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Dear Sirs: 
Anakinra is approved for rheumatoid arthritis, but is also effective in patients with adult-onset Still's disease. We 
present what is, to our knowledge, the first case published of depression related to anakinra use.  
 A 43-year-old man had been diagnosed with Still’s disease 18 months earlier. The diagnosis was based 
on chronic fever up to 39C, chronic inflammatory arthralgias, myalgias, major inflammatory biological 
syndrome (CRP 200 to 300 mg/L, fibrinogen 9 g/L, and neutrophils 20 to 30.10
9
/L), and the exclusion of any 
other diseases. Blood cultures, testing for infectious agents, skin testing for tuberculosis, and antinuclear 
antibodies, as well as antineutrophil cytoplasmic antibodies were negative. The patient had no medical history of 
any diseases or other medical conditions. Prednisolone was administered at 1mg/kg/d, which dramatically 
improved symptoms. When prednisolone was lowered to a dose of 0.5mg/kg/d per day, arthralgias and myalgias 
reappeared. Despite the introduction of methotrexate (20 mg weekly), prednisolone could not be lowered below 
20 mg daily. The patient’s general status remained altered by disabling pain. One year later, anakinra was 
initiated (100 mg subcutaneous daily) and arthralgias and myalgias promptly disappeared. Prednisolone was 
progressively reduced to 8 mg daily and methotrexate to 10 mg weekly.  
 Six weeks after beginning anakinra, the patient complained of depressive symptoms. Two months later, 
clinical and biological signs of the disease were controlled but depressive symptoms had worsened. The patient 
was unable to work, and was hospitalized in a psychiatric inpatient unit due to major depressive disorder with 
suicidal ideation. As the patient had no personal or family history of depressive symptoms and no recent 
psychological trauma, a pharmacological cause was suspected.  
 Anakinra, the last drug introduced prior to the depressive disorder, was discontinued, and the patient 
was treated with cyamemazine (75mg/d for 3 days), clonazepam (8 mg/d), and citalopram (20 mg/d). Within a 
few days, depressive symptoms improved, allowing for a reduction in psychiatric treatment after 1 week. 
Anakinra was not reintroduced, and depressive symptoms did not recur following clonazepam and citalopram 
cessation.  
 This case report suggests a “probable” link between depression and anakinra, as there was a temporal 
relationship between the beginning of anakinra treatment and the onset of depressive symptoms, and between the 
discontinuation of anakinra and the regression of depressive symptoms. It should be noted that the depressive 
symptoms did not recur after withdrawing psychotropic drugs. The role of metothrexate can be excluded because 
its dosage had been reduced prior to the onset of the patient’s depression and as depressive symptoms improved 
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despite the continuation of methotrexate treatment. The role of prednisolone can also be ruled out as depressive 
symptoms improved despite the continuation of this treatment.  
 A literature search did not reveal any case report of depression related to anakinra use. However, in one 
case of Crohn’s disease worsened by anakinra [1], the patient also reported depressive symptoms which 
disappeared after discontinuing anakinra therapy. Anakinra, a recombinant human interleukin-1 receptor 
antagonist (IL-1ra), acts as an IL-1 inhibitor and a significant association between high serum IL-1ra levels and 
depression was found in several studies [2]. Moreover, a significant positive relationship between serum IL-1ra 
level and the severity of depression was demonstrated [3] as documented by a higher risk of developing 
depressive symptoms over time in patients with high serum IL-1ra levels [4]. This cytokine could alter the 
activity of IDO (indoleamine 2,3-dioxygenase), a tryptophan metabolizing enzyme, thereby inducing changes in 
brain serotonine levels [5].A decrease in serotonin levels induced by IL-1ra could account for anakinra-related 
depression. 
 This first case report underlines the need to know this new side effect as it requires rapid anakinra 
cessation. 
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